USE OF CONTROLLED SUBSTANCES (THE RESEARCH OF THE NATURE AND THE EFFECTS OF MARIJUANA AND HALLUCINOGENIC DRUGS)

I. REFERENCES:

   A. 21 United States Code, 801 et seq. (Public Law 91-513).
   B. California Health and Safety Code, Sections 11655.5 and 11655.6.
   C. University of California Business and Finance Bulletin, BUS-50, Acquisition and Use of Narcotics and Dangerous Drugs.
   E. Vice President McCorkle's delegation of authority to Chancellors and Laboratory Directors, Registration and Acquisition of Narcotics and Dangerous Drugs, dated August 14, 1972.
   F. Chancellor Cheadle's delegation of authority to UCSB Materiel Manager, December 14, 1972.
   G. UCSB Research Circular No. 4-73, Policy on the Research of the Nature and the Effects of Marijuana and Hallucinogenic Drugs.

II. POLICY:

   The Controlled Substances Act, effective May 1, 1971, placed the control of narcotics and dangerous drugs under the jurisdiction of the U.S. Department of Justice, Drug Enforcement Administration.

   A. Schedules of Controlled Substances:

   Five schedules of controlled substances have been defined as follows (the composition of these schedules may change by amendment to the Controlled Substance Act):

   1. Schedule I Substances. Drugs in this schedule are those having a high potential for abuse, having no currently accepted medical use in the United States, or a lack of accepted safety. Some examples are: heroin, marijuana, LSD, peyote, mescaline, psilocybin, tetrahydrocannabinols, morphine methylsulfonate, and nicocodein.

   2. Schedule II Substances. The drugs in this schedule have a high potential for abuse, a currently accepted medical use in the United States, and their use may lead to severe psychological or physical dependence. Most of Schedule II Substances have been known in the past as Class A Narcotic
Drugs; some examples are: opium, morphine, codeine, dihydromorphinone (Dilaudid), methadone (Dolophine), pentopon, meperidine (Demerol), cocaine, oxycodone (Percodan). Also included in this Schedule is any compound which contains in any form the substance of methamphetamines as an injectable liquid.

3. Schedule III Substances. The drugs in this schedule have an abuse potential less than those listed in Schedules I and II, and include those drugs formerly known as Class B Narcotics, and non-narcotic drugs such as: glutethimide (Doriden), phenmetrazine (Preludin), methyprylon (Noludar), methylphenidate (Ritalin), nalorphine, and barbiturates (except phenobarbital, methylphenobarbital, and barbital). Paregoric is now listed in this schedule, as well as amphetamines and methamphetamines (except an injectable liquid).

4. Schedule IV Substances. The drugs in this schedule have an abuse potential less than those listed in Schedule III and includes drugs such as: barbital, phenobarbital, methylphenobarbital, chloral hydrate, ethchlorvynol (Placidyl), ethinamate (Valmid), meprobamate (Equanil, Miltown).

5. Schedule V Substances. The drugs in this schedule have an abuse potential less than those listed in Schedule IV, and consist of those preparations formerly known as Exempt Narcotics, with the exception of paregoric (Camphorated Tincture of Opium). Paregoric is now listed as a Schedule III Controlled Substance.

B. Registration:

1. Registration Classifications:

Of the registration classifications established by DEA and State Law, the following apply to this campus:

a. Teaching Institution; to be used for instruction purposes only, using Controlled Substances listed in Schedules II. through V.

b. Hospital Clinic; authority to dispense and to conduct institutional activities, using Controlled Substances listed in Schedules II. through V.

c. Research; to conduct research with narcotic and non-narcotic Controlled Substances listed in Schedules II through V.

d. Research; to conduct research with a Controlled Substance listed in Schedule I.

e. Chemical Analysis; (distinct from research); to conduct chemical analyses with Controlled Substances listed in any Schedule.

2. Extent of Registration
a. For each of the above registration classifications (paragraph III.B.1.) one registration covers all such activities on campus, except for classification III.B.1.d.

b. Classification III.B.1.d. requires a separate registration for each research project.

c. If an operation remote from the campus required Controlled Substances, a separate registration is necessary for each type of activity involved.

3. Filing Application for Registration

The campus Materiel Manager has been designated as the individual authorized to apply for campus and research registration and to procure Controlled Substances, and to coordinate the paperwork necessary to secure approval of the proposed activity from the Research Advisory Panel. Inquiries, including those pertaining to registration, procedures for procurement, security, required records and inventories, and authorized disposal of Controlled Substances, should be directed to the campus Office of Material Manager.

C. Research Proposals:

If a proposed research project involves the use of any Schedule I controlled substance, or human research utilizing any Schedule II controlled substance except those listed under stimulants, the DEA requires that a notice of approval of the proposed activity issued by the Research Advisory Panel be submitted along with the request for registration. The UCSB Contracts and Grants Office will be unable to process a proposal for mailing to the funding agency unless approval of the Panel is submitted along with the proposed application. (See paragraph II.B.3 above.)

1. The Research Advisory Panel

The Research Advisory Panel consists of representatives of: the State Department of Public Health, the State Department of Mental Hygiene, the Chairman of the Interagency Council on Drug Abuse, the California State Board of Pharmacy, the Attorney General's Office, and a private university selected annually by the Governor.

D. Report of Drug Abuse Project:

1. The California Health and Safety Code establishes The Regents of the University of California as the information exchange for drug abuse research and service projects. In turn, this responsibility has been delegated to the UCSF Department of Pharmacology and is referred to as the Drug Abuse Information Program (DAIP).

2. This program does not alter the general campus procedures for submitting proposals, but the statute does require the reporting of such projects promptly upon award, regardless of funding source; see Attachment A for the reporting form.
(UCSB/CGO Form No. 17).

III. ATTACHMENT:


Please direct questions about these policies to Meta.Clow@vcadmin.ucsb.edu. For questions or comments regarding the format of the above information, please contact webcontact@ucsbuxa.ucsb.edu.

Return to the UCSB home page.

Last Modified By: EBH, 7/09/98